CN115260160B - Compound of targeted fibroblast activation protein FAP, preparation method and application thereof - Google Patents
Compound of targeted fibroblast activation protein FAP, preparation method and application thereof Download PDFInfo
- Publication number
- CN115260160B CN115260160B CN202211006861.1A CN202211006861A CN115260160B CN 115260160 B CN115260160 B CN 115260160B CN 202211006861 A CN202211006861 A CN 202211006861A CN 115260160 B CN115260160 B CN 115260160B
- Authority
- CN
- China
- Prior art keywords
- cancer
- compound
- fap
- radionuclide
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 79
- 210000002950 fibroblast Anatomy 0.000 title claims abstract description 18
- 230000004913 activation Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 41
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 41
- 239000000539 dimer Substances 0.000 claims abstract description 39
- 230000008685 targeting Effects 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 230000002018 overexpression Effects 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 44
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 238000006482 condensation reaction Methods 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 238000002372 labelling Methods 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000000178 monomer Substances 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 4
- -1 carboxyl hydroxyl Chemical group 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000018883 protein targeting Effects 0.000 claims description 4
- QSJTUXCBPTVKQZ-JEDNCBNOSA-N (2s)-pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.N#C[C@@H]1CCCN1 QSJTUXCBPTVKQZ-JEDNCBNOSA-N 0.000 claims description 3
- UVKYGKPXDDWMIV-UHFFFAOYSA-N 6-hydroxyquinoline-4-carboxylic acid Chemical compound C1=C(O)C=C2C(C(=O)O)=CC=NC2=C1 UVKYGKPXDDWMIV-UHFFFAOYSA-N 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- SJMDMGHPMLKLHQ-UHFFFAOYSA-N tert-butyl 2-aminoacetate Chemical compound CC(C)(C)OC(=O)CN SJMDMGHPMLKLHQ-UHFFFAOYSA-N 0.000 claims description 3
- TZRQZPMQUXEZMC-UHFFFAOYSA-N tert-butyl n-(2-bromoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCBr TZRQZPMQUXEZMC-UHFFFAOYSA-N 0.000 claims description 3
- BOGMTOHWIVLVJE-WCCKRBBISA-N (2s)-4,4-difluoropyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.FC1(F)CN[C@H](C#N)C1 BOGMTOHWIVLVJE-WCCKRBBISA-N 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 2
- 208000005072 Oncogenic osteomalacia Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 238000010511 deprotection reaction Methods 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 2
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 231100000241 scar Toxicity 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 201000009377 thymus cancer Diseases 0.000 claims description 2
- 230000007838 tissue remodeling Effects 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 238000001819 mass spectrum Methods 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- 238000003384 imaging method Methods 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 239000012043 crude product Substances 0.000 description 11
- 125000004193 piperazinyl group Chemical group 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 5
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 229940125797 compound 12 Drugs 0.000 description 5
- 229940126543 compound 14 Drugs 0.000 description 5
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 4
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 4
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 description 4
- HBBSDZXXUIHKJE-UHFFFAOYSA-N 6-hydrazinylpyridine-3-carboxylic acid Chemical compound NNC1=CC=C(C(O)=O)C=N1 HBBSDZXXUIHKJE-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229940126142 compound 16 Drugs 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002386 leaching Methods 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- ICWDAESAANBIGG-LJAQVGFWSA-N OC(=O)CN1CCN(CC(O)=O)CCN(CC(=O)N2CCN(CCCOc3ccc4nccc(C(=O)NCC(=O)N5CC(F)(F)C[C@H]5C#N)c4c3)CC2)CCN(CC(O)=O)CC1 Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(=O)N2CCN(CCCOc3ccc4nccc(C(=O)NCC(=O)N5CC(F)(F)C[C@H]5C#N)c4c3)CC2)CCN(CC(O)=O)CC1 ICWDAESAANBIGG-LJAQVGFWSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- NKIJBSVPDYIEAT-UHFFFAOYSA-N 1,4,7,10-tetrazacyclododec-10-ene Chemical compound C1CNCCN=CCNCCN1 NKIJBSVPDYIEAT-UHFFFAOYSA-N 0.000 description 2
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 238000012879 PET imaging Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- XOYLJNJLGBYDTH-UHFFFAOYSA-M chlorogallium Chemical compound [Ga]Cl XOYLJNJLGBYDTH-UHFFFAOYSA-M 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052733 gallium Inorganic materials 0.000 description 2
- 229910052732 germanium Inorganic materials 0.000 description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- WUJUYHMGDPTLMG-UHFFFAOYSA-N imidazol-2-ylacetic acid Chemical compound OC(=O)CC1=NC=CN1 WUJUYHMGDPTLMG-UHFFFAOYSA-N 0.000 description 2
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- YGSRAYJBEREVRB-VIFPVBQESA-N (2s)-5-[(2-methylpropan-2-yl)oxy]-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid Chemical compound CC(C)(C)OC(=O)CC[C@@H](C(O)=O)NC(=O)OC(C)(C)C YGSRAYJBEREVRB-VIFPVBQESA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical class OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to a compound of a dimer of a target FAP protein, which has the following structural formulas (I) and (II), wherein R 1 、R 2 、R 3 And R is 4 The same or different are independently selected from H or F; z and U are the same or different connecting structures and are respectively and independently selected from-NH-or- (CH) -based 2 ) n -an alternative structure; q is selected fromOr alternativelyQ' is selected fromOr alternativelyW is the structure of a chelating species. The invention also provides radionuclide-labeled compounds based on the targeting compounds, and methods of preparing the same and use thereof in diagnosing or treating diseases characterized by overexpression of Fibroblast Activation Protein (FAP).
Description
Technical Field
The present invention relates to the fields of nuclear medicine and molecular imaging, in particular to a compound, a pharmaceutical composition comprising or consisting of said compound, a kit comprising or consisting of said compound or pharmaceutical composition, and the use of said compound or pharmaceutical composition in the diagnosis or treatment of a disease characterized by overexpression of Fibroblast Activation Protein (FAP).
Background
Fibroblast activation protein (Fibroblast activation protein, FAP) is a membrane serine peptidase expressed on the surface of tumor stroma activated fibroblasts and plays an important role in the development and progression of tumors. Previous studies have shown that FAP is not normally expressed in normal human tissues, but is selectively highly expressed on the surface of stromal fibroblasts of more than 90% of epithelial malignancies, including breast cancer, esophageal cancer, thyroid cancer, ovarian cancer, lung cancer, colorectal cancer, gastric cancer, pancreatic cancer, and the like. In view of its broad expression and important role in tumors, FAP has become an important target for tumor imaging and therapy.
Radionuclide-labeled Fibroblast Activation Protein Inhibitors (FAPI) represented by quinolinic acid derivatives have made important progress in the field of tumor precision imaging. For example, PET/CT imaging agents such as FAPI-02 and FAPI-04 have achieved more than 30 different types of tumor-specific imaging. The FAPI reported so far is rapidly cleared in the blood circulation and simultaneously eluted rapidly at the tumor site. This metabolic profile is very disadvantageous for treatment because rapid metabolism and elution results in lower effective doses at the tumor site, too short retention times, and the need to use high doses or more frequent dosing to meet the therapeutic needs, increasing the likelihood of adverse reactions. Based on multivalent effects, chen Hao et al (J nucleic Med.2022Jun;63 (6): 862-868) developed a dimer based on the FAPI46 structure, the structure of which is as follows:
such dimeric FAPI, while capable of increasing tumor uptake and residence time, have been observed to have higher physiological uptake in the kidneys, blood pool, liver, thyroid and pancreas. It is well known in the art that high background uptake in normal organs results in relatively low tumor to background ratios, which can affect the detection efficiency of diseased regions and increase the potential risk of therapeutic applications. Therefore, it is necessary to optimize the structure of dimer FAPI to have appropriate metabolism kinetics, higher tumor uptake dose and longer tumor retention time, and meet nuclide treatment and imaging requirements.
Disclosure of Invention
In view of the above background, a primary object of the present invention is: a new compound structure targeting Fibroblast Activation Protein (FAP) was developed.
Another object of the invention is: methods of preparing the novel compounds are provided.
A further object of the invention is: there is provided the use of said compounds in the diagnosis or treatment of diseases characterized by overexpression of Fibroblast Activation Protein (FAP).
The above object of the present invention is achieved by the following technical solutions:
in a first aspect, the present invention provides a dimer compound targeting FAP protein or a pharmaceutically acceptable salt thereof, the structure of the compound is shown in the following formula (I):
on the basis, the invention also provides a radiolabeled dimer compound targeting FAP protein or pharmaceutically usable salt thereof, the structure of the compound is shown as the following formula (II),
in the above formula (I) and formula (II):
R 1 、R 2 、R 3 and R is 4 The same or different are independently selected from H or F;
z and U are the same or different and are independently selected from-NH-or- (CH) -based 2 ) n -an alternative structure wherein n is an integer from 1 to 16, wherein each-CH 2 -with or without-O-, -NH-, - (CO) -, -NH- (CO) -, -CH (NH) alone 2 ) -or- (CO) -NH-substitution,the condition for substitution is that there are no two adjacent-CH 2 -the group is replaced;
In the above formula (II), W is a nuclide chelating moiety, is a group derived from a chelating radionuclide of any of 1,4,7, 10-tetraazacyclododecane-N, N ', N, N ' -tetraacetic acid (DOTA), ethylenediamine tetraacetic acid (EDTA), 1,4, 7-triazacyclononane-1, 4, 7-triacetic acid (NOTA), triethylenetetramine (TETA), iminodiacetic acid, diethylenetriamine-N, N, N ', N ', N ' -pentaacetic acid (DTPA), bis- (carboxymethyl imidazole) glycine or 6-hydrazinopyridine-3-carboxylic acid (HYNIC), or is any of the following structures:
wherein D is based on- (CH) 2 ) p -an alternative structure wherein p is an integer from 0 to 16, wherein each-CH 2 -with or without-O-, -NH-, - (CO) -, -NH- (CO) -, -CH (NH) alone 2 ) -or- (CO) -NH-substitution, provided that there are no two adjacent-CH 2 -the group is replaced.
In a preferred embodiment of the present invention, the compound of formula (I) has a structure represented by any one of the following formulas (I-1) to (I-3):
in a preferred embodiment of the present invention, the compound of formula (II) has a structure represented by any one of the following formulas (II-1) to (II-11):
further, the present invention also provides a radionuclide-labeled dimer compound targeting FAP protein, which is a radionuclide-labeled compound represented by the formula (II) of the present invention; the radionuclide may be selected from the group consisting of an alpha-emitting isotope, a beta-emitting isotope, a gamma-emitting isotope, an Auger electron-emitting isotope, an X-ray emitting isotope, etc., e.g 18 F、 51 Cr、 67 Ga、 68 Ga、 111 In、 99m Tc、 186 Re、 188 Re、 139 La、 140 La、 175 Yb、 153 Sm、 166 Ho、 86 Y、 90 Y、 149 Pm、 165 Dy、 169 Er、 177 Lu、 47 Sc、 142 Pr、 159 Gd、 212 Bi、 213 Bi、 72 As、 72 Se、 97 Ru、 109 Pd、 105 Rh、 101m Rh、 119 Sb、 128 Ba、 123 I、 124 I、 131 I、 197 Hg、 211 At、 151 Eu、 153 Eu、 169 Eu、 201 Tl、 203 Pb、 212 Pb、 64 Cu、 67 Cu、 198 Au、 225 Ac、 227 Th or Th 199 Any one of Ag; more preferred radionuclides are 18 F、 64 Cu、 68 Ga、 89 Zr、 90 Y、 111 In、 99m Tc、 177 Lu、 188 Re or 225 Ac。
The invention also provides pharmaceutically acceptable tautomers, racemates, hydrates, solvates or salts of said dimer compound targeting FAP protein, said dimer compound targeting FAP protein which can be labeled with a radionuclide, or said dimer compound targeting FAP protein which is labeled with a radionuclide.
In a second aspect, the present invention provides a method for preparing a dimer compound targeting FAP protein represented by formula (I), a compound represented by formula (II), and a radionuclide label thereof, comprising:
(1) preparation of monomers
Performing amide condensation reaction on carboxyl hydroxyl of 6-hydroxyquinoline-4-carboxylic acid and amino of glycine tert-butyl ester to obtain an intermediate I;
then, the hydroxyl of the intermediate I and N-Boc-bromoethylamine are subjected to condensation reaction to obtain an intermediate II containing protected amino and protected carboxyl;
performing amide condensation reaction on the carboxyl in the intermediate II after deprotection and (S) -pyrrolidine-2-carbonitrile hydrochloride or (S) -4, 4-difluoro pyrrolidine-2-carbonitrile hydrochloride to obtain an intermediate III containing protected amino;
the amino in the intermediate III is deprotected to obtain an intermediate IV, and the amino in the intermediate IV and the carboxyl hydroxyl of the tert-butyloxycarbonyl-L-glutamic acid-5-tert-butyl ester undergo condensation reaction to obtain an intermediate V containing protected amino and protected carboxyl;
(2) synthesis of dimers
Firstly, deprotecting carboxyl of an intermediate V, and carrying out condensation reaction with amino of any intermediate IV obtained in the step (1) to obtain an intermediate VI; the intermediate VI is deprotected to obtain the dimer compound of the target FAP protein;
(3) synthesis of dimeric compounds targeting FAP proteins that can be labeled with radionuclides
Removing the Boc protecting group of the intermediate VI; the chelating moiety W is introduced as a group from any one of 1,4,7, 10-tetraazacyclododecane-N, N ', N ' -tetraacetic acid (DOTA), ethylenediamine tetraacetic acid (EDTA), 1,4, 7-triazacyclononane-1, 4, 7-triacetic acid (NOTA), triethylenetetramine (TETA), iminodiacetic acid, diethylenetriamine-N, N ', N "-pentaacetic acid (DTPA), bis- (carboxymethyl imidazole) glycine or 6-hydrazinopyridine-3-carboxylic acid (HYNIC), or any one of the following structures:
wherein D is based on- (CH) 2 ) p -an alternative structure wherein p is an integer from 0 to 16, wherein each-CH 2 -with or without-O-, -NH-, - (CO) -, -NH- (CO) -, -CH (NH) alone 2 ) -or- (CO) -NH-substitution, provided that there are no two adjacent-CH 2 -the group is replaced; obtaining a radionuclide-labeled dimer compound of a target FAP protein, namely a compound shown in a formula (II);
(4) the radionuclide-labeled dimer compound of the target FAP protein obtained in the step (3) reacts with the radionuclide-containing compound according to the existing wet labeling method or freeze-drying labeling method, and the radionuclide-labeled dimer compound of the target FAP protein can be prepared.
In a third aspect, the present invention provides a pharmaceutical composition comprising a dimer compound targeting FAP protein according to the first aspect of the present invention, the dimer compound targeting FAP protein that can be labeled with a radionuclide, the dimer compound targeting FAP protein that is labeled with a radionuclide, or any tautomer, racemate, hydrate, solvate, or salt thereof that is pharmaceutically acceptable; or consists of the dimer compound targeting FAP protein, which can be labeled by a radionuclide, or any tautomer, racemate, hydrate, solvate or salt thereof which is pharmaceutically acceptable, and any pharmaceutically acceptable carrier and/or excipient.
In a fourth aspect, the present invention provides the use of a dimer compound targeting FAP protein as described in the first aspect, a dimer compound targeting FAP protein which can be labelled with a radionuclide, a dimer compound targeting FAP protein as described in the radionuclide, or a pharmaceutical composition as described in the third aspect, for the manufacture of a medicament for diagnosing or treating a disease characterized by overexpression of Fibroblast Activation Protein (FAP) in an animal or human subject.
In the use of the invention, the diseases characterized by the overexpression of Fibroblast Activation Protein (FAP) include, but are not limited to: cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and scar disease; preferably, the cancer is further selected from breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular carcinoma, esophageal cancer, hypopharynx cancer, nasopharyngeal cancer, laryngeal cancer, myeloma cells, bladder cancer, cholangiocellular carcinoma, clear cell renal cancer, neuroendocrine tumor, oncogenic osteomalacia, sarcoma, CUP (primary unknown cancer), thymus cancer, glioma, astrocytoma, cervical cancer, or prostate cancer.
In a fifth aspect, the present invention also provides a kit comprising or consisting of a compound of formula (I) according to the present invention, a compound of formula (II) according to the present invention, a radionuclide-labeled FAP protein-targeting dimer compound according to the present invention, or a pharmaceutical composition according to the present invention, and instructions for diagnosing a disease.
In the development of FAPI monomer, researchers have found that piperazine ring in FAPI structure plays an important role in maintaining tumor uptake, so adding piperazine ring into structure becomes a routine or customary means for designing FAPI probes in the art. It can also be seen from Chen Hao et al (J Nucl Med 2022Jun;63 (6): 862-868) that this design has been retained in the development of dimer FAPI. However, in research and development experiments, the inventor finds that the high-performance FAPI probe cannot be obtained by simple dimerization modification based on the existing FAPI monomer, but rather, the high background uptake occurs, so that the ratio of tumor to background in the aspect of organ uptake of the drug is low, and the performance is poor. The inventors have observed through extensive experimentation that the presence of a piperazine ring structure may adversely affect the pharmacokinetic properties of dimer FAPI. Therefore, the piperazine ring structure is not introduced in the synthesis of the dimer FAPI, and experiments prove that the prepared compound structure of the targeting FAP protein and the radiolabeled compound thereof have obviously improved tumor uptake effect compared with the existing dimer FAPI, and are expected to be applied to diagnosis or treatment of diseases characterized by over-expression of Fibroblast Activation Protein (FAP).
Drawings
FIG. 1 is a mass spectrum of Compound 2 in example 1 of the present invention.
FIG. 2 is a mass spectrum of Compound 6 in example 1 of the present invention.
FIG. 3 is a mass spectrum of Compound 8 in example 1 of the present invention.
FIG. 4 is a mass spectrum of compound 10 in example 1 of the present invention.
FIG. 5 is a mass spectrum of compound 11 of formula (I-1) in example 1 of the present invention.
FIG. 6 is a mass spectrum of Compound 12 in example 1 of the present invention.
FIG. 7 is a mass spectrum of Compound 14 in example 2 of the present invention.
FIG. 8 is a mass spectrum of compound 16 in example 2 of the present invention.
FIG. 9 is a mass spectrum of the formula (II-2) in example 3 of the present invention.
FIG. 10 is a mass spectrum of the intermediate of formula (II-3) in example 4 of the present invention.
FIG. 11 is a mass spectrum of the intermediate of formula (II-3) in example 4 of the present invention.
FIG. 12 is a mass spectrum of the formula (II-3) in example 4 of the present invention.
FIG. 13 is a mass spectrum of the formula (II-3) in example 4 of the present invention.
FIG. 14 is a mass spectrum of the formula (II-4) in example 5 of the present invention.
FIG. 15 is a mass spectrum of the formula (II-10) in example 6 of the present invention.
FIG. 16 is a schematic view of the present invention 68 A graph of the results of MicroPET imaging of Ga-labeled complexes of formula (I-1) in HT1080-hFAP tumor-bearing mice.
FIG. 17 shows the present invention 68 MicroPET imaging results of Ga-labeled FAPI46 complex in HT1080-hFAP tumor-bearing mice.
FIG. 18 is a graph showing the results of MicroPET imaging of a 68 Ga-labeled complex of formula (I-1) of the present invention in HT1080-hFAP tumor-bearing mice 1 hour after co-injection with FAPI-04.
FIG. 19 is a diagram of the present invention 68 Ga-labeled complex of formula (I-1) tumor and important organ uptake results statistics (horizontal axis in figure is different organs, and left to right columnar graph in each organ corresponds to each other respectively) after injection of HT1080-hFAP tumor-bearing mice for 1 hr, 2 hr and 4 hr 68 Uptake value of Ga-labeled complex of formula (I-1).
FIG. 20 shows the present invention 68 A graph of MicroPET imaging results of Ga-labeled F2 complexes in HT1080-hFAP tumor bearing mice.
FIG. 21 is a schematic view of an embodiment of the present invention 68 A graph of MicroPET imaging results of Ga-labeled F3 complexes in HT1080-hFAP tumor bearing mice.
Detailed Description
The technical scheme of the invention is further illustrated and described below by the specific embodiments in combination with the accompanying drawings.
Example 1: preparation of Compounds of formula II-1
Synthesis of Compound 2:
into a 100mL flask, compound 1 (6-hydroxyquinoline-4-carboxylic acid, 1.89g,10.0 mmol), tert-butyl glycinate (1.89 g,10.0 mmol), HATU (3.8 g,10.0 mmol) and N, N-diisopropylethylamine (2.6 g,20.0 mmol) were each charged successively to 30mL of N, N-dimethylformamide. The reaction mixture was stirred overnight, and the solvent was distilled off under reduced pressure to give a crude product. Purification over a silica gel column (dichloromethane/methanol=30:1) afforded compound 2 as a white solid in 87% yield. Fig. 1 is a mass spectrum of compound 2.
Synthesis of Compound 3:
in a 100mL flask, compound 2 (1.51 g,5.0 mmol), N-Boc-bromoethylamine (2.25 g,10.0 mmol), and potassium carbonate (1.38 g,10.0 mmol) were successively introduced into 50mL of N, N-dimethylformamide. The system was warmed to 60℃and kept under stirring at 60℃overnight, and the solvent was removed by distillation to give a crude product. Purification on a silica gel column (dichloromethane/methanol=30:1) gave compound 3 as a white solid in 51% yield.
Synthesis of Compound 5:
compound 4 (0.44 g,1.0 mmol) was dissolved in a mixed solution of 10mL of dichloromethane and trifluoroacetic acid (volume ratio: 9:1) under ice bath, the system was warmed to room temperature and reacted for 2 hours, the solvent was distilled off under reduced pressure after the completion of the reaction, 10mL of di-t-butyl dicarbonate (0.22 g,1.0 mmol) and N, N-diisopropylethylamine (0.39 g,3.0 mmol) were added, respectively, and stirred at room temperature overnight, and the solvent was distilled off under reduced pressure to give a crude product. Purification on a silica gel column (dichloromethane/methanol=10:1) gave compound 5 as a white solid in 77% yield.
Synthesis of Compound 6:
into a 100mL flask, compound 5 (0.39 g,1.0 mmol), (S) -pyrrolidine-2-carbonitrile hydrochloride (0.13 g,10.0 mmol), HATU (0.38 g,1.0 mmol) and N, N-diisopropylethylamine (0.26 g,2.0 mmol) were charged sequentially to 10mL of N, N-dimethylformamide. The reaction mixture was stirred at room temperature until the reaction was completed, and the solvent was distilled off under reduced pressure to obtain a crude product. Purification on a silica gel column (dichloromethane/methanol=30:1) gave compound 6 as a white solid in 82% yield. Fig. 2 is a mass spectrum of compound 6.
Synthesis of Compound 8:
compound 7 (0.55 g,1.0 mmol) and p-toluenesulfonic acid monohydrate (0.27 g,1.5 mmol) were each introduced into a 100mL flask, and then introduced into 10mL of acetonitrile. The reaction system was warmed to 60℃and stirred until the reaction was completed, the solvent was distilled off under reduced pressure, 10mL of N, N-dimethylformamide was dissolved, and tert-butoxycarbonyl-L-glutamic acid-5-tert-butyl ester (0.3 g,1.0 mmol), HATU (0.38 g,1.0 mmol) and N, N-diisopropylethylamine (0.26 g,2.0 mmol) were added, respectively. The reaction mixture was stirred until the reaction was completed, and the solvent was distilled off under reduced pressure to obtain a crude product. Purification on a silica gel column (dichloromethane/methanol=20:1) gave compound 8 as a white solid in 75% yield. FIG. 3 is a mass spectrum of Compound 8.
Synthesis of Compound 10:
compound 8 (0.65 g,1.0 mmol) was dissolved in a mixed solution of 10mL of dichloromethane and trifluoroacetic acid (volume ratio 9:1) under ice bath, the system was warmed up to room temperature for reaction for 2 hours, the solvent was distilled off under reduced pressure after the completion of the reaction, 10mL of N, N-dimethylformamide was dissolved, di-tert-butyl dicarbonate (0.22 g,1.0 mmol) and N, N-diisopropylethylamine (0.39 g,3.0 mmol) were added respectively, stirring was carried out at room temperature overnight, after the completion of the reaction, compound 7 (0.37 g,1.0 mmol), HATU (0.38 g,1.0 mmol) and N, N-diisopropylethylamine (0.26 g,2.0 mmol) were sequentially added to the system, and after the completion of the reaction, the solvent was distilled off under reduced pressure, the crude product was obtained.
Synthesis of Compound 12:
compound 7 (95 mg,0.1 mmol) and p-toluenesulfonic acid monohydrate (0.09 g,0.5 mmol) were each introduced into a 50mL flask, and then introduced into 5mL of acetonitrile. The reaction system was warmed to 60℃and stirred until the reaction was completed, the solvent was distilled off under reduced pressure, 5mL of N, N-dimethylformamide was dissolved, and DOTA-NHS (0.05 g,0.1 mmol) and N, N-diisopropylethylamine (0.04 g,0.3 mmol) were added in this order. The reaction system was stirred at room temperature and was monitored by HPLC until the reaction was completed, and the solvent was distilled off under reduced pressure to obtain a crude product. The crude product was purified by reverse phase column chromatography and freeze-dried to give pure compound 12 in 37% yield. Fig. 5 is a mass spectrum of compound 11, and fig. 6 is a mass spectrum of compound 12.
The synthetic route of the steps is as follows:
example 2: preparation of Compounds of formula II-7
Synthesis of Compound 14:
into a 50mL flask were charged compound 11 (85 mg,0.1 mmol), compound 13 (please provide the chemical name 52mg,0.1 mmol), HATU (38 mg,0.1 mmol) and N, N-diisopropylethylamine (39 mg,0.30 mmol) prepared in example 1, respectively. The reaction mixture was stirred overnight. After the completion of the reaction, the solvent was distilled off under reduced pressure to give a crude product. Purification over a silica gel column (dichloromethane/methanol=10:1) afforded compound 14 as a white solid in 54% yield. Fig. 7 is a mass spectrum of compound 14.
Synthesis of Compound 16:
compound 14 (67 mg,0.1 mmol) was dissolved in a mixed solution of 10mL of dichloromethane and trifluoroacetic acid (volume ratio 9:1) under ice bath conditions, the reaction was carried out at room temperature for 2 hours, the solvent was distilled off under reduced pressure after the completion of the reaction to give compound 15, and DOTA-NHS (0.05 g,0.1 mmol) and N, N-diisopropylethylamine (0.04 g,0.3 mmol) were added in this order after compound 15 was dissolved with 5mL of N, N-dimethylformamide. The reaction system was stirred at room temperature and was monitored by HPLC until the reaction was completed, and the solvent was distilled off under reduced pressure to obtain a crude product. The crude product was purified by reverse phase column chromatography and freeze-dried to give pure compound 16 in 39% yield. Fig. 8 is a mass spectrum of compound 16.
The synthetic route of the steps is as follows:
the structures of the compounds of examples 3-11 are shown as the formulas (II-2) to (II-6) and the formulas (II-8) to (II-11), respectively, and the preparation methods thereof can refer to the examples 1 and 2, so as to obtain the following corresponding structures:
example 12 preparation of a radioactive Ga-68 labeling complex:
wet process: about 18.5 to 1850 megabellum (MBq) 68 GaCl 3 Hydrochloric acid solution (eluted from gallium germanium generator) was added to a centrifuge tube containing 0.5mL of acetic acid-acetate solution (1.0 g/L) of compound 12 prepared in example 1, and reacted at 37℃for 20 minutes. A C18 separation column was taken, which was slowly rinsed with 10mL absolute ethanol followed by 10mL water. After diluting the labeling solution with 10mL of water, the solution was applied to a separation column, and unlabeled solution was removed with 10mL of water 68 Ga ion, and leaching by 0.3mL of 10mM HCl ethanol solution to obtain 68 Ga-labeled complexes. Diluting the leaching solution with normal saline, and sterile filtering to obtain 68 Ga-labeled injection of the complex of formula (II-1).
And (3) lyophilization: about 18.5 to 1850 megabellum (MBq) 68 GaCl 3 Hydrochloric acid solution (eluted from germanium gallium generator) was added to the lyophilized kit containing the labeled precursor, and reacted at 37 ℃ for 20min after mixing. A C18 separation column was taken, which was slowly rinsed with 10mL absolute ethanol followed by 10mL water. After diluting the labeling solution with 10mL of water, the solution was applied to a separation column, and unlabeled solution was removed with 10mL of water 68 Ga ions are leached by ethanol solution of 0.3ml of 10mM HCl to obtain complex leaching solution. Diluting the leaching solution with normal saline, and sterile filtering to obtain 68 Ga-labeled (II-1) complex injection.
Experimental example application Effect analysis
The complex of formula (II-1) prepared as in example 12 was injected into HT1080-hFAP tumor bearing mice (7.4 MBq) via the tail vein and then administered under isoflurane anesthesia at 0 th to third post-administrationMicroPET imaging was performed for 60 min. Figure 16 shows intravenous injection 68 MicroPET images of HT1080-hFAP tumor bearing mice at various times after the Ga-formula (II-1) complex, fig. 17 shows intravenous injection 68 MicroPET images of HT1080-hFAP tumor bearing mice after 1 hour of Ga-FAPI-46 complex. As can be seen from the view of figure 16, 68 ga-formula (II-1) complex is fast and high-efficiency ingested at tumor site, very low in most normal organs, and is mainly rapidly cleared through kidney. And monomer which has been widely used at present 68 Ga-FAPI46 in dimeric form 68 The uptake of Ga-formula (II-1) complexes in tumors is markedly increased. In addition, the above-mentioned 68 Ga-formula (II-1) complex and FAPI-04 are co-injected into HT1080-hFAP tumor-bearing mice, and the MicroPET imaging result chart is shown in FIG. 18, and co-injection leads to the rapid decrease of tumor uptake, and blocking experiments prove that 68 Ga-formula (II-1) complex can realize tumor specific targeting through FAP protein in vivo. In a biodistribution study, HT1080-hFAP mice were injected with 1.48MBq 68 Ga-formula (II-1) complex, after 1h, 2h and 4h (3 parallel experiments at each time point) after injection, respectively, separated, weighed, and gamma counter measured and analyzed for major organ and tumor radioactivity (counts per minute, cpm), the test results are shown in FIG. 19, consistent with PET imaging results, 68 ga-formula (II-1) complexes exhibit high uptake and high residence time in tumors, while normal organ uptake is very low.
In the development of FAPI monomers, previous studies have shown that piperazine rings in FAPI structures play an important role in maintaining tumor uptake. However, the present inventors have found through experiments that the presence of the piperazine ring structure may have an adverse effect on the pharmacokinetic properties of dimer FAPI, such that a higher background uptake occurs, resulting in a lower tumor to background ratio of the drug in terms of organ uptake. In this experiment, as a control, the researcher will have two piperazine ring structures 68 Ga-F2 (its labeling precursor structure is shown in FIG. 20) and piperazine ring 68 Ga-F3 (its labeled precursor structure is shown in FIG. 21) was injected into HT1080-hFAP tumor bearing mice via the tail vein (7.4 MBq) and subjected to MicroPET imaging. As can be seen from FIGS. 20 and 21, the structure of the piperazine ring is two 68 Ga-F2 has higher uptake in tumors, but also in kidneys; at the same time with a piperazine ring 68 Ga-F3 although the ratio of renal uptake 68 Ga-F2 was somewhat decreased, but higher uptake was observed at the joints. And is connected with 68 Ga-F2 68 Compared with Ga-F3, the dimer probe structure disclosed by the invention does not contain piperazine ring, and as shown in fig. 16 and 19, the dimer FAPI has excellent metabolic dynamics property, high tumor uptake and retention time and application potential.
In view of the above, the present invention has developed a novel fibroblast activation protein FAP targeting compound, which is expected to be applied to diagnosis or treatment of diseases characterized by overexpression of Fibroblast Activation Protein (FAP).
While the invention has been described in detail in the foregoing general description, embodiments and experiments, it will be apparent to those skilled in the art that modifications and improvements can be made thereto. Accordingly, such modifications or improvements may be made without departing from the spirit of the invention and are intended to be within the scope of the invention as claimed.
Claims (10)
2. radionuclide-labeled targeting FAP proteinA dimeric compound of formula (II-1) to formula (II-6) according to claim 1, wherein the dimeric compound is obtained by labeling a radionuclide; the radionuclide is selected from 18 F、 64 Cu、 68 Ga、 89 Zr、 90 Y、 111 In、 99m Tc、 177 Lu、 188 Re or 225 Ac。
3. A process for preparing a compound represented by the formulae (I-1) to (I-3) according to claim 1, comprising:
(1) preparation of monomers
Performing amide condensation reaction on carboxyl hydroxyl of 6-hydroxyquinoline-4-carboxylic acid and amino of glycine tert-butyl ester to obtain an intermediate I;
then, the hydroxyl of the intermediate I and N-Boc-bromoethylamine are subjected to condensation reaction to obtain an intermediate II containing protected amino and protected carboxyl;
performing amide condensation reaction on the carboxyl in the intermediate II after deprotection and (S) -pyrrolidine-2-carbonitrile hydrochloride or (S) -4, 4-difluoro pyrrolidine-2-carbonitrile hydrochloride to obtain an intermediate III containing protected amino;
the amino in the intermediate III is deprotected to obtain an intermediate IV, and the amino in the intermediate IV and the carboxyl hydroxyl of the tert-butyloxycarbonyl-L-glutamic acid-5-tert-butyl ester undergo condensation reaction to obtain an intermediate V containing protected amino and protected carboxyl;
(2) synthesis of dimers
Firstly, deprotecting carboxyl of an intermediate V, and carrying out condensation reaction with amino of any intermediate IV obtained in the step (1) to obtain an intermediate VI; the intermediate VI is deprotected to obtain the dimer compound of the target FAP protein shown in the formulas (I-1) to (I-3).
4. A process for preparing a compound represented by the formulae (II-1) to (II-6) according to claim 1, comprising:
removing the Boc protecting group of intermediate VI obtained in claim 3; introducing a chelating moiety W, W being any one of the following structures:
wherein D is-NH-;
to obtain a dimer compound which can be marked by radionuclides and targets FAP protein, namely, the compounds shown in formulas (II-1) to (II-6).
5. A method of preparing the radionuclide-labeled FAP protein-targeted dimer compound of claim 2, comprising: the radionuclide-labeled targeting compound can be prepared by reacting the compounds shown in the formulas (II-1) to (II-6) obtained in the claim 4 with a radionuclide-containing compound according to the existing wet labeling method or freeze-drying labeling method.
6. A pharmaceutical composition characterized by: a dimeric compound comprising any one of the FAP-targeted proteins of claim 1, any one of the radionuclide-labeled FAP-targeted dimeric compounds of claim 2, or a pharmaceutically acceptable salt thereof.
7. Use of a dimer compound targeting FAP protein of any one of formulae (II-1) to (II-6) as defined in claim 1, a dimer compound targeting FAP protein as defined in claim 2, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined in claim 6, for the manufacture of a medicament for the diagnosis or treatment of a disease characterized by overexpression of Fibroblast Activation Protein (FAP) in an animal or human subject.
8. The use according to claim 7, characterized in that: the diseases characterized by the overexpression of Fibroblast Activation Protein (FAP) include: cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and scar disease.
9. The use of claim 8, wherein the cancer is selected from the group consisting of breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular carcinoma, esophageal cancer, hypopharynx cancer, nasopharyngeal cancer, laryngeal cancer, myeloma cells, bladder cancer, cholangiocellular carcinoma, clear cell renal cancer, neuroendocrine tumor, oncogenic osteomalacia, sarcoma, CUP (primary unknown cancer), thymus cancer, glioma, astrocytoma, cervical cancer, and prostate cancer.
10. A kit comprising or consisting of: (1) a FAP protein-targeting dimer compound represented by any one of formulas (II-1) to (II-6) of claim 1, a radionuclide-labeled FAP protein-targeting dimer compound of claim 2, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 6; (2) instructions for diagnosing a disease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211006861.1A CN115260160B (en) | 2022-08-22 | 2022-08-22 | Compound of targeted fibroblast activation protein FAP, preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211006861.1A CN115260160B (en) | 2022-08-22 | 2022-08-22 | Compound of targeted fibroblast activation protein FAP, preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115260160A CN115260160A (en) | 2022-11-01 |
CN115260160B true CN115260160B (en) | 2023-06-20 |
Family
ID=83752693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211006861.1A Active CN115260160B (en) | 2022-08-22 | 2022-08-22 | Compound of targeted fibroblast activation protein FAP, preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115260160B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115433261B (en) * | 2022-11-07 | 2023-01-13 | 烟台蓝纳成生物技术有限公司 | RGD dimer compound and preparation method and application thereof |
CN115583989B (en) * | 2022-12-09 | 2023-02-28 | 烟台蓝纳成生物技术有限公司 | SSTR 2-targeted compound and preparation method and application thereof |
CN116120290A (en) * | 2023-03-01 | 2023-05-16 | 广东药科大学附属第一医院 | Preparation method of MR probe for targeting fibroblast activation protein |
CN118271393B (en) * | 2024-05-31 | 2024-09-03 | 中国药科大学 | FAP-targeted dimeric compound, probe and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114790193B (en) * | 2020-12-21 | 2024-05-10 | 苏州药明博锐生物科技有限公司 | Fibroblast activation protein inhibitor |
CN113582975A (en) * | 2021-07-03 | 2021-11-02 | 上海蓝纳成生物技术有限公司 | Truncated Evans blue modified fibroblast activation protein inhibitor and preparation method and application thereof |
CN113880810B (en) * | 2021-09-24 | 2023-02-28 | 厦门大学 | Nuclide-labeled complex and preparation method and application thereof |
-
2022
- 2022-08-22 CN CN202211006861.1A patent/CN115260160B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN115260160A (en) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115260160B (en) | Compound of targeted fibroblast activation protein FAP, preparation method and application thereof | |
KR101243016B1 (en) | Diagnostic compounds | |
CN115286697B (en) | Dual-targeting compound and preparation method and application thereof | |
US10201625B2 (en) | Radiolabelled octreotate analogues as PET tracers | |
CA3090812A1 (en) | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer | |
CN113372285B (en) | Prostate specific membrane antigen inhibitor, radionuclide marker, preparation method and application thereof | |
CN109438517B (en) | Complex of bifunctional linking agent coordinated with carbonyl metal core and preparation method thereof | |
CN114369084B (en) | Truncated Evans blue modified fibroblast activation protein inhibitor and preparation method and application thereof | |
CN113582975A (en) | Truncated Evans blue modified fibroblast activation protein inhibitor and preparation method and application thereof | |
CN118126024B (en) | Brand-new skeleton 99mTc-FAPI diagnostic probe and application thereof in preparation of tumor diagnosis drugs or reagents | |
CN115505032A (en) | Fibroblast activation protein FAP and integrin alpha v β 3 Dual-targeting compound and preparation method and application thereof | |
CN116751259A (en) | Fibroblast activation protein FAP and integrin alpha v β 3 Dual targeting compounds and methods of making the same | |
EP4387944A1 (en) | Radiopharmaceuticals, methods for the production thereof, and uses in treatment, diagnosis and imaging diseases | |
CN115974962B (en) | FAP-targeted probe and preparation method and application thereof | |
WO2024099245A1 (en) | Rgd dimer compound, and preparation method therefor and use thereof | |
JP5085824B2 (en) | Production of compounds useful for hypoxia detection | |
WO2023236778A1 (en) | Trifunctional compound and use thereof | |
JP5774687B2 (en) | Tricarbonyltechnesium-99m or rhenium-188-labeled cyclic RGD derivative, method for producing the same, and pharmaceutical composition for diagnosis or treatment of neovascular diseases involving the same as an active ingredient | |
WO2022170732A1 (en) | Truncated evans blue modified fibroblast activation protein inhibitor, preparation method therefor, and application thereof | |
CN118271393B (en) | FAP-targeted dimeric compound, probe and application thereof | |
CN115368342B (en) | Fibroblast active protein inhibitor, radionuclide marker, preparation method and application thereof | |
US20220072165A1 (en) | Radiodrug for diagnostic/therapeutic use in nuclear medicine and radio-guided medicine | |
US20130156701A1 (en) | Method of preparing ethacrynic amide derivatives and application thereof | |
Iannone et al. | Automated radiosynthesis and preclinical evaluation of two new PSMA-617 derivatives radiolabelled via [18F] AlF2+ method | |
CN116547293A (en) | Radioactive metal complex for targeting prostate specific membrane antigen and labeled ligand thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |